Ironwood Pharmaceuticals Management
Management criteria checks 3/4
Ironwood Pharmaceuticals' CEO is Tom McCourt, appointed in Mar 2021, has a tenure of 3.08 years. total yearly compensation is $7.89M, comprised of 10.2% salary and 89.8% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $4.67M. The average tenure of the management team and the board of directors is 2.7 years and 5 years respectively.
Key information
Tom McCourt
Chief executive officer
US$7.9m
Total compensation
| CEO salary percentage | 10.2% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.7yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16
Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29Ironwood Pharmaceuticals: Undervalued Company With Steady Growth
Sep 27Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today
Jul 21Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Jun 22Ironwood Pharmaceuticals names Thomas McCourt permanent CEO
Jun 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$1b |
| Sep 30 2023 | n/a | n/a | -US$952m |
| Jun 30 2023 | n/a | n/a | -US$917m |
| Mar 31 2023 | n/a | n/a | US$182m |
| Dec 31 2022 | US$8m | US$805k | US$175m |
| Sep 30 2022 | n/a | n/a | US$168m |
| Jun 30 2022 | n/a | n/a | US$173m |
| Mar 31 2022 | n/a | n/a | US$527m |
| Dec 31 2021 | US$9m | US$732k | US$528m |
| Sep 30 2021 | n/a | n/a | US$530m |
| Jun 30 2021 | n/a | n/a | US$509m |
| Mar 31 2021 | n/a | n/a | US$143m |
| Dec 31 2020 | US$3m | US$576k | US$106m |
| Sep 30 2020 | n/a | n/a | US$111m |
| Jun 30 2020 | n/a | n/a | US$97m |
| Mar 31 2020 | n/a | n/a | US$84m |
| Dec 31 2019 | US$5m | US$511k | US$59m |
| Sep 30 2019 | n/a | n/a | US$19m |
| Jun 30 2019 | n/a | n/a | -US$153m |
| Mar 31 2019 | n/a | n/a | -US$173m |
| Dec 31 2018 | US$2m | US$465k | -US$194m |
| Sep 30 2018 | n/a | n/a | -US$190m |
| Jun 30 2018 | n/a | n/a | -US$71m |
| Mar 31 2018 | n/a | n/a | -US$108m |
| Dec 31 2017 | US$2m | US$450k | -US$55m |
Compensation vs Market: Tom's total compensation ($USD7.89M) is above average for companies of similar size in the US market ($USD5.57M).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
CEO
Tom McCourt (66 yo)
3.1yrs
Tenure
US$7,893,266
Compensation
Mr. Thomas A. McCourt, also known as Tom, serves as Director at Pliant Therapeutics, Inc. since March 2023. He serves as Chief Executive Officer and Director of Ironwood Pharmaceuticals, Inc. since June 02...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 10.2yrs | US$337.03k | 0.10% $ 1.3m | |
| CEO & Director | 3.1yrs | US$7.89m | 0.37% $ 4.7m | |
| Senior VP | 2.3yrs | US$712.36k | 0.11% $ 1.4m | |
| Senior VP | 2.7yrs | US$2.41m | 0.086% $ 1.1m | |
| Chief Medical Officer | 5.3yrs | US$2.92m | 0.17% $ 2.2m | |
| Corporate Controller & Principal Accounting Officer | 5yrs | no data | 0.029% $ 365.7k | |
| Vice President of Technical Operations | 3.3yrs | no data | no data | |
| Vice President of Strategic Finance & Investor Relations | no data | no data | no data | |
| Head of Corporate Communications & Media Relations | 2.3yrs | no data | no data | |
| Vice President of Sales & Sales Excellence | 2.6yrs | no data | no data | |
| Senior VP & Chief Business Officer | 2.3yrs | no data | 0.12% $ 1.5m | |
| VP & Head of Clinical Development | 1.6yrs | no data | no data |
2.7yrs
Average Tenure
46yo
Average Age
Experienced Management: IRWD's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 10.2yrs | US$337.03k | 0.10% $ 1.3m | |
| CEO & Director | 2.8yrs | US$7.89m | 0.37% $ 4.7m | |
| Director | 3.3yrs | US$302.03k | 0.065% $ 824.1k | |
| Member of Pharmaceuticals Advisory Committee | no data | no data | no data | |
| Independent Director | 3.4yrs | US$299.90k | 0.078% $ 982.8k | |
| Director | 5yrs | US$296.40k | 0.35% $ 4.4m | |
| Independent Director | 8yrs | US$307.03k | 0.11% $ 1.4m | |
| Member of Pharmaceutical Advisory Committee | 7.2yrs | no data | no data | |
| Independent Director | 5yrs | US$312.02k | 0.082% $ 1.0m | |
| Independent Director | 5yrs | US$299.53k | 0.062% $ 778.4k | |
| Independent Director | 5yrs | US$304.53k | 0.077% $ 975.5k |
5.0yrs
Average Tenure
64yo
Average Age
Experienced Board: IRWD's board of directors are considered experienced (5 years average tenure).